Skip to main content

Diagnostics device for rapid testing of prostate cancer at Point-of-care

Project description

Urine test for prostate cancer

As Europeans live longer, prostate cancer is being diagnosed in a higher proportion of elderly men. As a common form of cancer, it’s also age-related. The disease is common above 65 but infrequent below the age of 40. By 2030, when the proportion of people over 65 will be higher, the number of prostate cancer cases is estimated to quadruple. Early detection is key to reducing the mortality rate. In this context, the EU-funded Nevada project proposes a non invasive urine-based test assay that identifies those men at increased risk of prostate cancer. The project aims to further simplify the test to convert it into a point-of-care assay.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

MDXHEALTH
Net EU contribution
€ 50 000,00
Address
Rue D'abhooz 31
4040 Herstal
Belgium

See on map

Region
Région wallonne Prov. Liège Arr. Liège
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 50 000,00